基于前两周累积食管剂量与局部体积变化早期预测急性食管炎
本研究针对局部晚期非小细胞肺癌放疗患者,利用前两周每周CBCT累积食管剂量及食管局部体积变化构建早期急性食管炎(≥2级)预测模型。该模型有望早期指导自适应放疗计划调整以降低食管炎风险。
要点
- 前两周食管局部体积变化参数VE10%、VE5%和最大膨胀百分比可显著预测≥2级急性食管炎。
- 联合第2周累积平均剂量与VE10%的模型预测性能最佳,AUC=0.80。
- 该模型在CBCT和MRI验证队列中AUC分别为0.78和0.75,优于仅用计划剂量模型。
核心结论
- 基于前两周CBCT累积食管剂量与局部体积变化的联合模型可较传统仅用计划剂量模型更准确预测≥2级急性食管炎。
研究设计与样本
- 前两周食管CBCT与计划CT形变配准后累积每周食管剂量,计算体积变化参数,用逻辑回归和5折交叉验证建模。
- 模型在额外18例每周CBCT和11例每周MRI患者中验证,并与仅用计划平均剂量的模型比较。
主要发现
- 联合第2周累积平均剂量与第1到2周VE10%的模型性能最佳(AUC=0.80;PHL=0.43)。
- 仅用计划平均剂量的模型准确性较低(AUC=0.67;PHL=0.26)。
- 联合模型在CBCT验证中AUC=0.78,在MRI验证中AUC=0.75。
关键数值与推荐
- 急性食管炎分级采用≥2级作为预测终点,中位发生时间为放疗开始后4周。
- 体积变化参数包括最大食管膨胀百分比(MEex%)和局部膨胀≥x%的体积(VEx%;x=5、10、15)。
- 联合模型采用第2周累积平均剂量(MEDW2)与第1到2周VE10%组合,交叉验证AUC=0.80。
临床怎么用
- 可在放疗前两周利用每周CBCT累积剂量和食管局部体积变化早期识别≥2级急性食管炎高风险患者。
- 预测高风险者可考虑早期进行自适应计划调整以降低食管炎风险。
局限性
- 研究为单中心设计,外部泛化性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute esophagitis (AE) is a common dose-limiting toxicity in radiation therapy of locally advanced non-small cell lung cancer (LA-NSCLC). We developed an early AE prediction model from weekly accumulated esophagus dose and its associated local volumetric change. METHODS AND MATERIALS: Fifty-one patients with LA-NSCLC underwent treatment with intensity modulated radiation therapy to 60 Gy in 2-Gy fractions with concurrent chemotherapy and weekly cone beam computed tomography (CBCT). Twenty-eight patients (55%) developed grade ≥2 AE (≥AE2) at a median of 4 weeks after the start of radiation therapy. For early ≥AE2 prediction, the esophagus on CBCT of the first 2 weeks was deformably registered to the planning computed tomography images, and weekly esophagus dose was accumulated. Week 1-to-week 2 (w1→w2) esophagus volume changes including maximum esophagus expansion (MEex%) and volumes with ≥x% local expansions (VEx%; x = 5, 10, 15) were calculated from the Jacobian map of deformation vector field gradients. Logistic regression model with 5-fold cross-validation was built using combinations of the accumulated mean esophagus doses (MED) and the esophagus change parameters with the lowest P value in univariate analysis. The model was validated on an additional 18 and 11 patients with weekly CBCT and magnetic resonance imaging (MRI), respectively, and compared with models using only planned mean dose (MEDPlan). Performance was assessed using area under the curve (AUC) and Hosmer-Lemeshow test (PHL). RESULTS: Univariately, w1→w2 VE10% (P = .004), VE5% (P = .01) and MEex% (P = .02) significantly predicted ≥AE2. A model combining MEDW2 and w1→w2 VE10% had the best performance (AUC = 0.80; PHL = 0.43), whereas the MEDPlan model had a lower accuracy (AUC = 0.67; PHL = 0.26). The combined model also showed high accuracy in the CBCT (AUC = 0.78) and MRI validations (AUC = 0.75). CONCLUSIONS: A CBCT-based, cross-validated, and internally validated model on MRI with a combination of accumulated esophagus dose and local volume change from the first 2 weeks of chemotherapy significantly improved AE prediction compared with conventional models using only the planned dose. This model could inform plan adaptation early to lower the risk of esophagitis.
引用
- Alam SR, Zhang P, Zhang SY, et al. Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33453309. doi:10.1016/j.ijrobp.2021.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。